We are live on ! Find out more
NTGN

Neon Therapeutics, Inc. Common Stock
NTGN

Delisted

NTGN was delisted on the 5th of May, 2020.

Back to rankings

45 hedge funds and large institutions have $169M invested in Neon Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

22% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 18

10% more funds holding

Funds holding: 41 → 45 (+4)

28% less capital invested

Capital invested by funds: $233M → $169M (-$64.6M)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
1.03%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
22
Increased
12
Reduced
6
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PIM
Partner Investment Management
California
+$9.2M
2
MIH
Meitav Investment House
Israel
+$7.19M
3
PI
Pharmstandard International
Luxembourg
+$6.52M
4
BlackRock
BlackRock
New York
+$3.05M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.5M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.55M
2
Millennium Management
Millennium Management
New York
-$2.02M
3
PC
PointState Capital
New York
-$1.89M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.57M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$81K +$106K +9,534 New
AIG
27
American International Group
New York
$36K +$46.4K +4,185 New
Barclays
28
Barclays
United Kingdom
$35K +$45.5K +4,109 New
TRCT
29
Tower Research Capital (TRC)
New York
$33K +$43.3K +3,907 New
HIIFS
30
Harel Insurance Investments & Financial Services
Israel
$26K +$22.2K +2,000 +200%
Wells Fargo
31
Wells Fargo
California
$18K +$12.1K +1,092 +109%
CHP
32
Cable Hill Partners
Oregon
$16K +$16.6K +1,500 New
Citigroup
33
Citigroup
New York
$15K +$19.6K +1,764 New
SO
34
STRS Ohio
Ohio
$15K +$20K +1,800 New
PCM
35
Prelude Capital Management
New York
$14K +$18.2K +1,642 New
UBS Group
36
UBS Group
Switzerland
$13K +$16.2K +1,460 +4,171%
JP Morgan Chase
37
JP Morgan Chase
New York
$12K -$607K -54,739 -97%
Legal & General Group
38
Legal & General Group
United Kingdom
$9K +$11.3K +1,024 New
WSTAM
39
Wilbanks Smith & Thomas Asset Management
Virginia
$5K +$6.65K +600 New
JCM
40
Jacobi Capital Management
Pennsylvania
$4K – – –
AIP
41
Ameritas Investment Partners
Nebraska
$4K +$5.38K +485 New
IUHSA
42
Itau Unibanco Holding S.A.
Brazil
$2K -$211 -19 -7%
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$2K +$3.48K +314 New
Millennium Management
44
Millennium Management
New York
– -$2.02M -160,507 Closed
PC
45
PointState Capital
New York
– -$1.89M -150,000 Closed
Alyeska Investment Group
46
Alyeska Investment Group
Illinois
– -$1.57M -125,000 Closed
Citadel Advisors
47
Citadel Advisors
Florida
– -$1.47M -116,418 Closed
Norges Bank
48
Norges Bank
Norway
– -$945K -75,000 Closed
WMSA
49
Weiss Multi-Strategy Advisers
New York
– -$907K -71,981 Closed
Goldman Sachs
50
Goldman Sachs
New York
– -$788K -62,500 Closed
1
2
3

NTGN Hedge Fund Activity: Q3 2018 in Review

45 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q3 2018, worth a combined $169M — down 28% from $233M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new NTGN positions and 18 closed out — a net gain of 4 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Partner Investment Management, adding an estimated $9.2M. The largest seller was Fidelity Investments, cutting an estimated $2.55M.

  • 45 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q3 2018, up from 41 in Q2 2018.
  • Funds reported $169M of Neon Therapeutics, Inc. Common Stock stock for Q3 2018, down 28% quarter-over-quarter.
  • 22 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q3 2018 and 18 closed out, a net change of +4 holders.
  • The largest Neon Therapeutics, Inc. Common Stock buyer in Q3 2018 was Partner Investment Management, an estimated $9.2M added.
  • The largest Neon Therapeutics, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $2.55M sold.

Based on aggregated 13F filings for Q3 2018.